Michael J Birrer, PhD, MD

Full Member

Research Program:

Cancer Biology

Faculty Rank:

Vice Chancellor and Director, WPR Cancer Institute

Campus:

University of Arkansas for Medical Sciences

College:

College of Medicine

Department:

Internal Medicine

Cancer Research Interest

Research Focus Area: Prevention, Treatment, Informatics, Detection, Carcinogenesis, Diagnosis/ Prognosis
Type of Research: Clinical, Population Sciences
Research Interest Statement: My lab is dedicated to the elucidation of the genomic basis for ovarian cancer. The lab has systematically analyzed the global gene.

Contact Information

Email Address: MJBIRRER@UAMS.EDU
Profiles Research Networking Software: View Profile

Open Clinical Trials

“An Open Label, Phase 1, Treatment Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of IDE397 (MAT2A Inhibitor) in Adult Participants with Advanced Solid Tumors” (NCT04794699)
“An Open-Label, Phase 1b Study of SL-172154 (SIRPa-Fc-CD40L) Administered with Either Pegylated Liposomal Doxorubicin or Mirvetuximab Soravtansine in Subjects with Platinum-Resistant Ovarian Cancers ” (NCT05483933)
“A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients with Advanced Solid Tumors” (NCT05252416)
“A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors” (NCT04657068)

Active Grants

Children's Tumor Foundation – CTF-2022-12-002
“Adult NF Clinic Program Building Pilot Project”
Co-Investigator
07/01/22 – 06/30/24
US Department of Defense – W81XWH-16-2-0038-P00003
“The Genomic, Epigenomic, and Quality-of-Life Characteristics of Long-Term Survivors of Ovarian Cancer”
Principal Investigator
03/15/21 – 12/25/23
NIH/Nat. Cancer Institute – 3U10CA180868
“NRG Oncology Network Group Operation Center”
Principal Investigator
03/01/21 – 02/28/25
US Department of Defense – W81XWH-17-1-0225
“Treatment of Recurrent, Platinum-Resistant Ovarian Cancer with Glutaminase 1 and PARP Inhibitors”
Principal Investigator
12/15/20 – 12/14/23

Publications

Arend R, Dholakia J, Castro C, [et al., including Birrer M]. DKK1 is a predictive biomarker for response to DKN-01: Results of a phase 2 basket study in women with recurrent endometrial carcinoma. Gynecologic oncology. 2023 172:82-91. PMID: 37001446.
LaFargue CJ, Amero P, Noh K, [et al., including Birrer MJ]. Overcoming adaptive resistance to anti-VEGF therapy by targeting CD5L. Nature communications. 2023 14(1):2407. PMID: 37100807. PMCID: PMC10133315.
Tewari KS, Sill MW, Birrer MJ, [et al.]. Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized study. Gynecologic oncology. 2023 171:141-150. PMID: 36898292. PMCID: PMC10286827.
Osann K, Wenzel L, McKinney C, [et al., including Birrer M]. Fear of recurrence, emotional well-being and quality of life among long-term advanced ovarian cancer survivors. Gynecologic oncology. 2023 171:151-158. PMID: 36905875.
Penson RT, Ambrosio AJ, Whalen CA, [et al., including Birrer MJ]. Phase II Trials of Iniparib (BSI-201) in Combination with Gemcitabine and Carboplatin in Patients with Recurrent Ovarian Cancer. The oncologist. 2023. PMID: 36718018. PMCID: PMC10020803.
Sato S, Gillette M, de Santiago PR, [et al., including Birrer MJ]. LINE-1 ORF1p as a candidate biomarker in high grade serous ovarian carcinoma. Scientific reports. 2023 13(1):1537. PMID: 36707610. PMCID: PMC9883229.
Banerjee S, Drapkin R, Richardson DL, Birrer M. Targeting NaPi2b in ovarian cancer. Cancer treatment reviews. 2023 112:102489. PMID: 36446254.
Campos S, Matulonis U, Berlin S, [et al., including Birrer MJ]. A randomized phase II trial of bevacizumab vs. bevacizumab and erlotinib as first-line consolidation after carboplatin, paclitaxel, and bevacizumab in newly diagnosed patients with mullerian tumors. International journal of clinical oncology. 2022 27(12):1881-1890. PMID: 36344654.
Farley JH, Brady WE, O'Malley D, [et al., including Birrer MJ]. A phase II evaluation of temsirolimus with carboplatin and paclitaxel followed by temsirolimus consolidation in clear cell ovarian cancer: An NRG oncology trial. Gynecologic oncology. 2022 167(3):423-428. PMID: 36244829. PMCID: PMC9789681.
Casablanca Y, Wang G, Lankes HA, [et al., including Birrer MJ]. Improving Risk Assessment for Metastatic Disease in Endometrioid Endometrial Cancer Patients Using Molecular and Clinical Features: An NRG Oncology/Gynecologic Oncology Group Study. Cancers. 2022 14(17). PMID: 36077609. PMCID: PMC9454742.
Chowdhury S, Wang R, Yu Q, [et al., including Birrer MJ]. DAGBagM: learning directed acyclic graphs of mixed variables with an application to identify protein biomarkers for treatment response in ovarian cancer. BMC bioinformatics. 2022 23(1):321. PMID: 35931981. PMCID: PMC9354326.
Birrer MJ, Fujiwara K, Oaknin A, [et al.]. The Changing Landscape of Systemic Treatment for Cervical Cancer: Rationale for Inhibition of the TGF-β and PD-L1 Pathways. Frontiers in oncology. 2022 12:814169. PMID: 35280818. PMCID: PMC8905681.
Huang D, Chowdhury S, Wang H, [et al., including Birrer MJ]. Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer. Cell reports. Medicine. 2021 2(12):100471. PMID: 35028612. PMCID: PMC8714940.
Swisher EM, Aghajanian C, O'Malley DM, [et al., including Birrer MJ]. Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study. Gynecologic oncology. 2021. PMID: 34906376.
Bigelow EO, Harris J, Fakhry C, [et al., including Birrer MJ]. Risk stratification after recurrence of human papillomavirus (HPV)-related and non-HPV-related oropharyngeal cancer: Secondary analysis of NRG Oncology RTOG 0129 and 0522. Head & neck. 2021. PMID: 34729846. PMCID: PMC8783635.
Huang D, Savage SR, Calinawan AP, [et al., including Birrer MJ]. A highly annotated database of genes associated with platinum resistance in cancer. Oncogene. 2021 40(46):6395-6405. PMID: 34645978. PMCID: PMC8602037.
Monk BJ, Colombo N, Oza AM, [et al., including Birrer MJ]. Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial. The Lancet. Oncology. 2021. PMID: 34363762.
Krasner CN, Campos SM, Young CL, [et al., including Birrer MJ]. Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer. Gynecologic oncology. 2021. PMID: 34243976.
Grushko TA, Filiaci VL, Montag AG, [et al., including Birrer MJ]. Effects of Slide Storage on Detection of Molecular Markers by IHC and FISH in Endometrial Cancer Tissues From a Clinical Trial: An NRG Oncology/GOG Pilot Study. Applied immunohistochemistry & molecular morphology : AIMM. 2021. PMID: 34224438. PMCID: PMC8664981.
Martinez A, Buckley M, Scalise CB, [et al., including Birrer MJ]. Understanding the effect of mechanical forces on ovarian cancer progression. Gynecologic oncology. 2021. PMID: 33888338. PMCID: PMC9115803.
Zhu Y, Ferri-Borgogno S, Sheng J, [et al., including Birrer MJ]. SIO: A Spatioimageomics Pipeline to Identify Prognostic Biomarkers Associated with the Ovarian Tumor Microenvironment. Cancers. 2021 13(8). PMID: 33917869. PMCID: PMC8068305.
Wenzel L, Osann K, McKinney C, [et al., including Birrer M]. Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival. Journal of the National Cancer Institute. 2021. PMID: 33729494. PMCID: PMC8486331.
Buechel ME, Enserro D, Burger RA, [et al., including Birrer MJ]. Correlation of imaging and plasma based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC). Gynecologic oncology. 2021. PMID: 33712274. PMCID: PMC8327185.
Moore KN, Oza AM, Colombo N, [et al., including Birrer MJ]. Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I. Annals of oncology : official journal of the European Society for Medical Oncology. 2021. PMID: 33667670.
Merritt MA, Strickler HD, Hutson AD, [et al., including Birrer MJ]. Sex Hormones, Insulin, and Insulin-like Growth Factors in Recurrence of High-Stage Endometrial Cancer. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2021. PMID: 33622671. PMCID: PMC8026669.
Chi RA, van der Watt P, Wei W, [et al., including Birrer MJ]. Inhibition of Kpnβ1 mediated nuclear import enhances cisplatin chemosensitivity in cervical cancer. BMC cancer. 2021 21(1):106. PMID: 33530952. PMCID: PMC7852134.
Martinez A, Buckley MS, Scalise CB, [et al., including Birrer MJ]. Utilization of a 3-D tissue engineered model to investigate the effects of perfusion on gynecologic cancer biology. Journal of tissue engineering. 2021 12:20417314211055015. PMID: 34820113. PMCID: PMC8606733.
Roane BM, Meza-Perez S, Katre AA, [et al., including Birrer MJ]. Neutralization of TGFβ Improves Tumor Immunity and Reduces Tumor Progression in Ovarian Carcinoma. Molecular cancer therapeutics. 2020. PMID: 33323456. PMCID: PMC7933076.
Betella I, Turbitt WJ, Szul T, [et al., including Birrer MJ]. Corrigendum to 'Wnt signaling modulator DKK1 as an immunotherapeutic target in ovarian cancer' [Gynecologic Oncology 157 (2020) 765-774]. Gynecologic oncology. 2020 159(1):295. PMID: 32839025.
Moore KN, Birrer MJ, Marsters J, [et al.]. Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer. Gynecologic oncology. 2020 158(3):631-639. PMID: 32534811.
Tewari KS, Sill MW, Monk BJ, [et al., including Birrer MJ]. Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology-Gynecologic Oncology Group Study 240 (NCT 00803062). Molecular cancer therapeutics. 2020. PMID: 32847980. PMCID: PMC7907274.
Da Silva DM, Enserro DM, Mayadev JS, [et al., including Birrer MJ]. Immune Activation in Patients with Locally Advanced Cervical Cancer Treated with Ipilimumab Following Definitive Chemoradiation (GOG-9929). Clinical cancer research : an official journal of the American Association for Cancer Research. 2020. PMID: 32816895. PMCID: PMC7642021.
Geistlinger L, Oh S, Ramos M, [et al., including Birrer MJ]. Multiomic Analysis of Subtype Evolution and Heterogeneity in High-Grade Serous Ovarian Carcinoma. Cancer research. 2020. PMID: 32747365. PMCID: PMC7572645.
Santin AD, Filiaci V, Bellone S, [et al., including Birrer MJ]. Corrigendum to "Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG oncology study (NRG-GY008)" [Gynecol. Oncol. Rep. 31 (2020) 100532]. Gynecologic oncology reports. 2020 33:100590. PMID: 32885014. PMCID: PMC7452617.
Myers AP, Konstantinopoulos PA, Barry WT, [et al., including Birrer M]. Phase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer. International journal of cancer. 2020 147(2):413-422. PMID: 31714586. PMCID: PMC7214201.
Arend RC, Beer HM, Cohen YC, [et al., including Birrer MJ]. Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I/II study are associated with an immunotherapeutic effect. Gynecologic oncology. 2020 157(3):578-584. PMID: 32265057.
Betella I, Turbitt WJ, Szul T, [et al., including Birrer MJ]. Wnt signaling modulator DKK1 as an immunotherapeutic target in ovarian cancer. Gynecologic oncology. 2020 157(3):765-774. PMID: 32192732.
O'Malley DM, Matulonis UA, Birrer MJ, [et al.]. Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer. Gynecologic oncology. 2020 157(2):379-385. PMID: 32081463.
Qi R, Wang Y, Bruno PM, [et al., including Birrer MJ]. Author Correction: Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer. Nature communications. 2020 11(1):1940. PMID: 32303677. PMCID: PMC7165165.
Santin AD, Deng W, Frumovitz M, [et al., including Birrer M]. Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002). Gynecologic oncology. 2020 157(1):161-166. PMID: 31924334. PMCID: PMC7127981.
Goldsberry WN, Meza-Perez S, Londoño AI, [et al., including Birrer MJ]. Inhibiting WNT Ligand Production for Improved Immune Recognition in the Ovarian Tumor Microenvironment. Cancers. 2020 12(3). PMID: 32213921. PMCID: PMC7140065.
Alvarez Secord A, Bell Burdett K, Owzar K, [et al., including Birrer MJ]. Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 26(6):1288-1296. PMID: 31919136. PMCID: PMC7073274.
Oza AM, Matulonis UA, Alvarez Secord A, [et al., including Birrer MJ]. A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 26(5):1009-1016. PMID: 31831561. PMCID: PMC7056559.
Krill L, Deng W, Eskander R, [et al., including Birrer M]. Overexpression of enhance of Zeste homolog 2 (EZH2) in endometrial carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. Gynecologic oncology. 2020 156(2):423-429. PMID: 31843273. PMCID: PMC7103063.
Schwede M, Waldron L, Mok SC, [et al., including Birrer MJ]. The Impact of Stroma Admixture on Molecular Subtypes and Prognostic Gene Signatures in Serous Ovarian Cancer. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2020 29(2):509-519. PMID: 31871106. PMCID: PMC7448721.
Arend RC, Davis AM, Chimiczewski P, [et al., including Birrer MJ]. EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade ovarian cancer. Gynecologic oncology. 2020 156(2):301-307. PMID: 31870556.
Santin AD, Filiaci V, Bellone S, [et al., including Birrer MJ]. Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG Oncology study (NRG-GY008). Gynecologic oncology reports. 2020 31:100532. PMID: 31934607. PMCID: PMC6951478.
Makhlouf H, Watson MA, Lankes HA, [et al., including Birrer M]. Toward Improving Practices for Submission of Diagnostic Tissue Blocks for National Cancer Institute Clinical Trials. American journal of clinical pathology. 2020 153(2):149-155. PMID: 31613330. PMCID: PMC7169836.
Doo DW, Meza-Perez S, Londoño AI, [et al., including Birrer MJ]. Inhibition of the Wnt/β-catenin pathway enhances antitumor immunity in ovarian cancer. Therapeutic advances in medical oncology. 2020 12:1758835920913798. PMID: 32313567. PMCID: PMC7158255.
Arend R, Martinez A, Szul T, Birrer MJ. Biomarkers in ovarian cancer: To be or not to be. Cancer. 2019 125 Suppl 24:4563-4572. PMID: 31967683.
Westin SN, Sill MW, Coleman RL, [et al., including Birrer MJ]. Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study. Gynecologic oncology. 2019 155(3):420-428. PMID: 31623857. PMCID: PMC6922584.
Yeung TL, Leung CS, Yip KP, [et al., including Birrer MJ]. Anticancer Immunotherapy by MFAP5 Blockade Inhibits Fibrosis and Enhances Chemosensitivity in Ovarian and Pancreatic Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 25(21):6417-6428. PMID: 31332047. PMCID: PMC6825539.
Mirza MR, Bergmann TK, Mau-Sørensen M, [et al., including Birrer MJ]. A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24. Cancer chemotherapy and pharmacology. 2019 84(4):791-798. PMID: 31375879.
Mirza MR, Åvall Lundqvist E, Birrer MJ, [et al.]. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial. The Lancet. Oncology. 2019 20(10):1409-1419. PMID: 31474354.
Tewari KS, Burger RA, Enserro D, [et al., including Birrer MJ]. Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 37(26):2317-2328. PMID: 31216226. PMCID: PMC6879307.
Thorsson V, Gibbs DL, Brown SD, [et al., including Birrer M J in Cancer Genome Atlas Research Network]. The Immune Landscape of Cancer. Immunity. 2019 51(2):411-412. PMID: 31433971.
Lee EK, Tan-Wasielewski Z, Matulonis UA, [et al., including Birrer MJ]. Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer. Gynecologic oncology reports. 2019 29:118-122. PMID: 31467965. PMCID: PMC6712364.
Matulonis UA, Shapira-Frommer R, Santin AD, [et al., including Birrer M]. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. Annals of oncology : official journal of the European Society for Medical Oncology. 2019 30(7):1080-1087. PMID: 31046082.
Birrer MJ, Moore KN, Betella I, Bates RC. Antibody-Drug Conjugate-Based Therapeutics: State of the Science. Journal of the National Cancer Institute. 2019 111(6):538-549. PMID: 30859213.
Ceppi L, Bardhan NM, Na Y, [et al., including Birrer MJ]. Real-Time Single-Walled Carbon Nanotube-Based Fluorescence Imaging Improves Survival after Debulking Surgery in an Ovarian Cancer Model. ACS nano. 2019 13(5):5356-5365. PMID: 31009198.
Roane BM, Arend RC, Birrer MJ. Review: Targeting the Transforming Growth Factor-Beta Pathway in Ovarian Cancer. Cancers. 2019 11(5). PMID: 31091744. PMCID: PMC6562901.
Randall LM, Birrer MJ, Herzog TJ. Ovarian Cancer Maintenance: Practice-Changing Data Calls for Changing Practice. The oncologist. 2019 24(5):576-579. PMID: 30894410. PMCID: PMC6516122.
Brooks RA, Tritchler DS, Darcy KM, [et al., including Birrer MJ]. GOG 8020/210: Risk stratification of lymph node metastasis, disease progression and survival using single nucleotide polymorphisms in endometrial cancer: An NRG oncology/gynecologic oncology group study. Gynecologic oncology. 2019 153(2):335-342. PMID: 30827726. PMCID: PMC6486855.
Krasner CN, Castro C, Penson RT, [et al., including Birrer MJ]. Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of Müllerian origin. Gynecologic oncology. 2019 153(2):223-229. PMID: 30765148.
Zaborowski MP, Lee K, Na YJ, [et al., including Birrer MJ]. Methods for Systematic Identification of Membrane Proteins for Specific Capture of Cancer-Derived Extracellular Vesicles. Cell reports. 2019 27(1):255-268.e6. PMID: 30943406. PMCID: PMC6528836.
Birrer MJ, Betella I, Martin LP, Moore KN. Is Targeting the Folate Receptor in Ovarian Cancer Coming of Age?. The oncologist. 2019 24(4):425-429. PMID: 30635448. PMCID: PMC6459241.
Konstantinopoulos PA, Barry WT, Birrer M, [et al.]. Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. The Lancet. Oncology. 2019 20(4):570-580. PMID: 30880072. PMCID: PMC7025391.
Barry WT, Birrer M, Buckanovich RJ, [et al.]. Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2019 30(4):551-557. PMID: 30753272. PMCID: PMC6503628.
Matulonis UA, Birrer MJ, O'Malley DM, [et al.]. Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody-Drug Conjugate Mirvetuximab Soravtansine. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 25(6):1727-1736. PMID: 30413525.
Rauh-Hain JA, Hidrue MK, Gaccione P, [et al., including Birrer MJ]. Variation in resource utilization associated with the surgical management of ovarian cancer. Gynecologic oncology. 2019 152(3):587-593. PMID: 30579568. PMCID: PMC6420848.
Elias KM, Tsantoulis P, Tille JC, [et al., including Birrer M]. Primordial germ cells as a potential shared cell of origin for mucinous cystic neoplasms of the pancreas and mucinous ovarian tumors. The Journal of pathology. 2018 246(4):459-469. PMID: 30229909. PMCID: PMC6240919.
Yeung TL, Tsai CC, Leung CS, [et al., including Birrer MJ]. ISG15 Promotes ERK1 ISGylation, CD8+ T Cell Activation and Suppresses Ovarian Cancer Progression. Cancers. 2018 10(12). PMID: 30469497. PMCID: PMC6316352.
Wang Y, Xu X, Maglic D, [et al., including Birrer M J in Cancer Genome Atlas Research Network]. Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer. Cell reports. 2018 25(5):1304-1317.e5. PMID: 30380420. PMCID: PMC6326181.
Korkut A, Zaidi S, Kanchi RS, [et al., including Birrer M J in Cancer Genome Atlas Research Network]. A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-β Superfamily. Cell systems. 2018 7(4):422-437.e7. PMID: 30268436. PMCID: PMC6370347.
Chen GM, Kannan L, Geistlinger L, [et al., including Birrer M]. Consensus on Molecular Subtypes of High-Grade Serous Ovarian Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 24(20):5037-5047. PMID: 30084834. PMCID: PMC6207081.
Moore KN, O'Malley DM, Vergote I, [et al., including Birrer MJ]. Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer. Gynecologic oncology. 2018 151(1):46-52. PMID: 30093227.
Caumanns JJ, Berns K, Wisman GBA, [et al., including Birrer MJ]. Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 24(16):3928-3940. PMID: 29685880. PMCID: PMC6098697.
Kahles A, Lehmann KV, Toussaint NC, [et al., including Birrer M J in Cancer Genome Atlas Research Network]. Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients. Cancer cell. 2018 34(2):211-224.e6. PMID: 30078747. PMCID: PMC9844097.
Bailey MH, Tokheim C, Porta-Pardo E, [et al., including Birrer M J in Cancer Genome Atlas Research Network]. Comprehensive Characterization of Cancer Driver Genes and Mutations. Cell. 2018 174(4):1034-1035. PMID: 30096302. PMCID: PMC8045146.
Moore KN, Vergote I, Oaknin A, [et al., including Birrer MJ]. FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer. Future oncology (London, England). 2018 14(17):1669-1678. PMID: 29424243.
Ricketts CJ, De Cubas AA, Fan H, [et al., including Birrer M J in Cancer Genome Atlas Research Network]. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Cell reports. 2018 23(12):3698. PMID: 29925010.
Hyman DM, Rizvi N, Natale R, [et al., including Birrer M]. Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 24(12):2749-2757. PMID: 29559563. PMCID: PMC6386190.
Moore KN, Birrer MJ. Administration of the Tablet Formulation of Olaparib in Patients with Ovarian Cancer: Practical Guidance and Expectations. The oncologist. 2018 23(6):697-703. PMID: 29593098. PMCID: PMC6067940.
Dizon DS, Dias-Santagata D, Bregar A, [et al., including Birrer M]. Complete Remission Following Pembrolizumab in a Woman with Mismatch Repair-Deficient Endometrial Cancer and a Germline BRCA1 Mutation. The oncologist. 2018 23(6):650-653. PMID: 29472312. PMCID: PMC6067948.
Liu Y, Sethi NS, Hinoue T, [et al., including Birrer M J in Cancer Genome Atlas Research Network]. Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. Cancer cell. 2018 33(4):721-735.e8. PMID: 29622466. PMCID: PMC5966039.
Wang Z, Yang B, Zhang M, [et al., including Birrer M J in Cancer Genome Atlas Research Network]. lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer. Cancer cell. 2018 33(4):706-720.e9. PMID: 29622465. PMCID: PMC6143179.
Berger AC, Korkut A, Kanchi RS, [et al., including Birrer M J in Cancer Genome Atlas Research Network]. A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. Cancer cell. 2018 33(4):690-705.e9. PMID: 29622464. PMCID: PMC5959730.
Taylor AM, Shih J, Ha G, [et al., including Birrer M J in Cancer Genome Atlas Research Network]. Genomic and Functional Approaches to Understanding Cancer Aneuploidy. Cancer cell. 2018 33(4):676-689.e3. PMID: 29622463. PMCID: PMC6028190.
Bailey MH, Tokheim C, Porta-Pardo E, [et al., including Birrer M J in Cancer Genome Atlas Research Network]. Comprehensive Characterization of Cancer Driver Genes and Mutations. Cell. 2018 173(2):371-385.e18. PMID: 29625053. PMCID: PMC6029450.
Hoadley KA, Yau C, Hinoue T, [et al., including Birrer M J in Cancer Genome Atlas Network]. Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. Cell. 2018 173(2):291-304.e6. PMID: 29625048. PMCID: PMC5957518.
Ding L, Bailey MH, Porta-Pardo E, [et al., including Birrer M J in Cancer Genome Atlas Research Network]. Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. Cell. 2018 173(2):305-320.e10. PMID: 29625049. PMCID: PMC5916814.
Sanchez-Vega F, Mina M, Armenia J, [et al., including Birrer M J in Cancer Genome Atlas Research Network]. Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell. 2018 173(2):321-337.e10. PMID: 29625050. PMCID: PMC6070353.
Malta TM, Sokolov A, Gentles AJ, [et al., including Birrer M J in Cancer Genome Atlas Research Network]. Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. Cell. 2018 173(2):338-354.e15. PMID: 29625051. PMCID: PMC5902191.
Huang KL, Mashl RJ, Wu Y, [et al., including Birrer M J in Cancer Genome Atlas Research Network]. Pathogenic Germline Variants in 10,389 Adult Cancers. Cell. 2018 173(2):355-370.e14. PMID: 29625052. PMCID: PMC5949147.
Chen H, Peng X, Zhou Z, [et al., including Birrer M J in Cancer Genome Atlas Research Network]. A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples. Cell. 2018 173(2):386-399.e12. PMID: 29625054. PMCID: PMC5890960.
Lichtenberg T, Hoadley KA, Poisson LM, [et al., including Birrer M J in Cancer Genome Atlas Research Network]. An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. Cell. 2018 173(2):400-416.e11. PMID: 29625055. PMCID: PMC6066282.
Ricketts CJ, De Cubas AA, Fan H, [et al., including Birrer M J in Cancer Genome Atlas Research Network]. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Cell reports. 2018 23(1):313-326.e5. PMID: 29617669. PMCID: PMC6075733.
Saltz J, Gupta R, Hou L, [et al., including Birrer M J in Cancer Genome Atlas Research Network]. Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images. Cell reports. 2018 23(1):181-193.e7. PMID: 29617659. PMCID: PMC5943714.
Campbell JD, Yau C, Bowlby R, [et al., including Birrer M J in Cancer Genome Atlas Research Network]. Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. Cell reports. 2018 23(1):194-212.e6. PMID: 29617660. PMCID: PMC6002769.
Ge Z, Leighton JS, Wang Y, [et al., including Birrer M J in Cancer Genome Atlas Research Network]. Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types. Cell reports. 2018 23(1):213-226.e3. PMID: 29617661. PMCID: PMC5916807.
Gao Q, Liang WW, Foltz SM, [et al., including Birrer M J in Cancer Genome Atlas Research Network]. Driver Fusions and Their Implications in the Development and Treatment of Human Cancers. Cell reports. 2018 23(1):227-238.e3. PMID: 29617662. PMCID: PMC5916809.
Knijnenburg TA, Wang L, Zimmermann MT, [et al., including Birrer M J in Cancer Genome Atlas Research Network]. Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas. Cell reports. 2018 23(1):239-254.e6. PMID: 29617664. PMCID: PMC5961503.
Peng X, Chen Z, Farshidfar F, [et al., including Birrer M J in Cancer Genome Atlas Research Network]. Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers. Cell reports. 2018 23(1):255-269.e4. PMID: 29617665. PMCID: PMC5916795.
Jayasinghe RG, Cao S, Gao Q, [et al., including Birrer M J in Genome Atlas Research Network]. Systematic Analysis of Splice-Site-Creating Mutations in Cancer. Cell reports. 2018 23(1):270-281.e3. PMID: 29617666. PMCID: PMC6055527.
Seiler M, Peng S, Agrawal AA, [et al., including Birrer M J in Cancer Genome Atlas Research Network]. Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types. Cell reports. 2018 23(1):282-296.e4. PMID: 29617667. PMCID: PMC5933844.
Chiu HS, Somvanshi S, Patel E, [et al., including Birrer M J in Cancer Genome Atlas Research Network]. Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context. Cell reports. 2018 23(1):297-312.e12. PMID: 29617668. PMCID: PMC5906131.
Banerjee S, Oza AM, Birrer MJ, [et al.]. Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study. Annals of oncology : official journal of the European Society for Medical Oncology. 2018 29(4):917-923. PMID: 29401246.
Ellrott K, Bailey MH, Saksena G, [et al., including Birrer M J in Cancer Genome Atlas Research Network]. Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. Cell systems. 2018 6(3):271-281.e7. PMID: 29596782. PMCID: PMC6075717.
Schaub FX, Dhankani V, Berger AC, [et al., including Birrer M J in Cancer Genome Atlas Network]. Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas. Cell systems. 2018 6(3):282-300.e2. PMID: 29596783. PMCID: PMC5892207.
Norquist BM, Brady MF, Harrell MI, [et al., including Birrer MJ]. Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 24(4):777-783. PMID: 29191972. PMCID: PMC5815909.
Qi R, Wang Y, Bruno PM, [et al., including Birrer MJ]. Publisher Correction: Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer. Nature communications. 2018 9(1):628. PMID: 29416025. PMCID: PMC5803230.
Leung CS, Yeung TL, Yip KP, [et al., including Birrer MJ]. Cancer-associated fibroblasts regulate endothelial adhesion protein LPP to promote ovarian cancer chemoresistance. The Journal of clinical investigation. 2018 128(2):589-606. PMID: 29251630. PMCID: PMC5785271.
Hamilton CA, Miller A, Casablanca Y, [et al., including Birrer MJ]. Clinicopathologic characteristics associated with long-term survival in advanced epithelial ovarian cancer: an NRG Oncology/Gynecologic Oncology Group ancillary data study. Gynecologic oncology. 2018 148(2):275-280. PMID: 29195926. PMCID: PMC5918685.
Moore KN, Martin LP, O'Malley DM, [et al., including Birrer MJ]. A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer. Future oncology (London, England). 2018 14(2):123-136. PMID: 29098867.
Moore KN, Martin LP, O'Malley DM, [et al., including Birrer M]. A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer. Future Oncology. 2018 14(2):123-136.
Qi R, Wang Y, Bruno PM, [et al., including Birrer MJ]. Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer. Nature communications. 2017 8(1):2166. PMID: 29255160. PMCID: PMC5735131.
Noh K, Mangala LS, Han HD, [et al., including Birrer MJ]. Differential Effects of EGFL6 on Tumor versus Wound Angiogenesis. Cell reports. 2017 21(10):2785-2795. PMID: 29212026. PMCID: PMC5749980.
Devor EJ, Miecznikowski J, Schickling BM, [et al., including Birrer MJ]. Dysregulation of miR-181c expression influences recurrence of endometrial endometrioid adenocarcinoma by modulating NOTCH2 expression: An NRG Oncology/Gynecologic Oncology Group study. Gynecologic oncology. 2017 147(3):648-653. PMID: 28969912. PMCID: PMC5698180.
Norquist BM, Brady MF, Harrell MI, [et al., including Birrer M]. Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study. Clinical Cancer Research: An Official Journal of the American Association of Cancer Research. 2017 24(4):777-783.
Tsang TY, Wei W, Itamochi H, [et al., including Birrer MJ]. Integrated genomic analysis of clear cell ovarian cancers identified PRKCI as a potential therapeutic target. Oncotarget. 2017 8(57):96482-96495. PMID: 29228547. PMCID: PMC5722499.
Wei W, Giulia F, Luffer S, [et al., including Birrer MJ]. How can molecular abnormalities influence our clinical approach. Annals of oncology : official journal of the European Society for Medical Oncology. 2017 28(suppl_8):viii16-viii24. PMID: 29232470.
Wei W, Giulia F, Luffer S, [et al., including Birrer MJ]. How can molecular abnormalities influence our clinical approach. Annals of oncology : official journal of the European Society for Medical Oncology. 2017 28 Suppl 8:viii16-viii24. PMID: 31952653.
Bais C, Mueller B, Brady MF, [et al., including Birrer MJ]. Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses. Journal of the National Cancer Institute. 2017 109(11). PMID: 29059426. PMCID: PMC5440032.
Moore KN, Tritchler D, Kaufman KM, [et al., including Birrer MJ]. Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecologic oncology. 2017 147(2):396-401. PMID: 28935272. PMCID: PMC5706110.
Martin LP, Konner JA, Moore KN, [et al., including Birrer MJ]. Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine. Gynecologic oncology. 2017 147(2):402-407. PMID: 28843653. PMCID: PMC6893864.
Oliver KE, Brady WE, Birrer M, [et al.]. An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience. Gynecologic oncology. 2017 147(2):243-249. PMID: 28807367. PMCID: PMC5697899.
Coleman RL, Oza AM, Lorusso D, [et al., including Birrer M J in ARIEL3 Investigators]. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London, England). 2017 390(10106):1949-1961. PMID: 28916367. PMCID: PMC5901715.
Tewari KS, Sill MW, Penson RT, [et al., including Birrer MJ]. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet (London, England). 2017 390(10103):1654-1663. PMID: 28756902. PMCID: PMC5714293.
Moore KN, Borghaei H, O'Malley DM, [et al., including Birrer MJ]. Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors. Cancer. 2017 123(16):3080-3087. PMID: 28440955. PMCID: PMC6896318.
Tsang TY, Wei W, Itamochi H, [et al., including Birrer M]. Integrated genomic analysis of clear cell ovarian cancers identified PRKCI as a potential therapeutic target. Oncotarget. 2017 8(57):96482-96495.
Reyes HD, Miecznikowski J, Gonzalez-Bosquet J, [et al., including Birrer MJ]. High stathmin expression is a marker for poor clinical outcome in endometrial cancer: An NRG oncology group/gynecologic oncology group study. Gynecologic oncology. 2017 146(2):247-253. PMID: 28532857. PMCID: PMC5526627.
Tao Z, Dang X, Huang X, [et al., including Birrer MJ]. Early tumor detection afforded by in vivo imaging of near-infrared II fluorescence. Biomaterials. 2017 134:202-215. PMID: 28482280.
Grabosch S, Tseng G, Edwards RP, [et al., including Birrer M]. Multiplex profiling identifies distinct local and systemic alterations during intraperitoneal chemotherapy for ovarian cancer: An NRG Oncology/Gynecologic Oncology Group Study. Gynecologic oncology. 2017 146(1):137-145. PMID: 28483269. PMCID: PMC5705948.
Phelan CM, Kuchenbaecker KB, Tyrer JP, [et al., including Birrer MJ]. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature genetics. 2017 49(5):680-691. PMID: 28346442. PMCID: PMC5612337.
Moore KN, Martin LP, O'Malley DM, [et al., including Birrer MJ]. Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 35(10):1112-1118. PMID: 28029313. PMCID: PMC5559878.
Cancer Genome Atlas Research Network [including Birrer M J]. Integrated genomic and molecular characterization of cervical cancer. Nature. 2017 543(7645):378-384. PMID: 28112728. PMCID: PMC5354998.
Gockley A, Melamed A, Bregar AJ, [et al., including Birrer M]. Outcomes of Women With High-Grade and Low-Grade Advanced-Stage Serous Epithelial Ovarian Cancer. Obstetrics and gynecology. 2017 129(3):439-447. PMID: 28178043. PMCID: PMC5328143.
Matulonis UA, Wulf GM, Barry WT, [et al., including Birrer M]. Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2017 28(3):512-518. PMID: 27993796. PMCID: PMC5834157.
Xiao H, Qi R, Li T, [et al., including Birrer MJ]. Maximizing Synergistic Activity When Combining RNAi and Platinum-Based Anticancer Agents. Journal of the American Chemical Society. 2017 139(8):3033-3044. PMID: 28166401.
Yazinski SA, Comaills V, Buisson R, [et al., including Birrer MJ]. ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells. Genes & development. 2017 31(3):318-332. PMID: 28242626. PMCID: PMC5358727.
McCourt CK, Deng W, Dizon DS, [et al., including Birrer MJ]. A phase II evaluation of ixabepilone in the treatment of recurrent/persistent carcinosarcoma of the uterus, an NRG Oncology/Gynecologic Oncology Group study. Gynecologic oncology. 2017 144(1):101-106. PMID: 28029447. PMCID: PMC5362250.
Lax T, Dizon DS, Birrer M, [et al.]. Extended carboplatin infusion does not reduce frequency of hypersensitivity reaction at initiation of retreatment in patients with recurrent platinum-sensitive ovarian cancer. The journal of allergy and clinical immunology. In practice. 2017 5(1):177-178. PMID: 27641482.
Birrer M, Ceppi L. Translational Advances in Gynecologic Cancers. Elsevier, 2017.
Del Carmen MG, Supko JG, Horick NK, [et al., including Birrer MJ]. Phase 1 and 2 study of carboplatin and pralatrexate in patients with recurrent, platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer. Cancer. 2016 122(21):3297-3306. PMID: 27421044.
Moore KN, Birrer MJ, Berlin S, [et al.]. Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2016 27(11):2124-2130. PMID: 27793850.
Waldron L, Riester M, Ramos M, [et al., including Birrer M]. The Doppelgänger Effect: Hidden Duplicates in Databases of Transcriptome Profiles. Journal of the National Cancer Institute. 2016 108(11). PMID: 27381624. PMCID: PMC5241903.